Mean (SEM) HBV DNA levels change from baseline through the end of the treatment period by Cohort Conclusion: All dose levels of ALG-000184 were well tolerated, exhibited predictable PK, and resulted in similar, substantial antiviral activity in untreated CHB subjects, regardless of HBeAg status.